Bharat Biotech Scales Up Covaxin Production To 700 Million Doses Annually

COVID-19 Vaccine: Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the globe with another 60 in the process, it added.

To support vaccination campaigns in India and across the globe, Bharat Biotech has ramped up the manufacturing capacity of its COVID-19 vaccine, Covaxin, to 700 million doses per annum, the vaccine maker said on Tuesday. Manufacturing scale up has been carried out in a step-wise manner across multiple facilities at Hyderabad and Bangalore, the company said in a statement. Sources told news agency Press Trust of India the company had a production capacity of 200 million doses of Covaxin in the beginning. Meanwhile, the chairman and managing director of Bharat Biotech, Krishna Ella, during an event said that the company will produce 30 million doses of Covaxin next month against around 20 million doses this month and 15 million in the last month.